# Forensic Dossier: Study Forensics: Amyloid-targeting antibody improves biomarkers without cognitive benefit

**Run ID:** `mc2_study-forensics-029_claude_haiku_be5254`  
**Task:** study-forensics-029 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-06T16:23:20.858424+00:00  
**Task Family:** solid  
**Trap Type:** borderline_solid_with_caveats  
**Ambiguity:** medium  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **73.8/100** (margin: 0.0)
**Failure modes:** missed_key_insight, named_not_explained, unsupported_conclusion, unsupported_intermediate_step
**Forensic flags:** 5
**Consistency findings:** 5
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 30.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 3.9/6 | 6.0/6 | 4.8/8 | 8.0/8 | 1.5/10 | 10.0/10 | **73.8/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `solid` [+] (gold: `solid`)
**Finding Recall:** 50%
**Matched Findings:** cautious_scope_control
**Missed Findings:** evidence_matches_claim
**Extra Findings:** none_or_minor, conclusion_exceeds_results, decorative_uncertainty, mechanism_not_demonstrated, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "solid"


## Forensic Flags

### Claude Haiku

- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "solid"
- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "solid"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"
- **[MINOR]** `study_forensics_overflagging`: Agent raised extra findings in solid case: none_or_minor, conclusion_exceeds_results, decorative_uncertainty, mechanism_not_demonstrated, correlation_as_causation


## Evidence Map

### Claude Haiku

**Correctness:** 30.0/30
  - (+) `final_answer`: "solid"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 0.0/8
  - (-) `final_answer`: "solid"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[6]`: "Evaluated the investigators' response: Proposing an open-label extension is reasonable given biomarker success, but they"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[1]`: "Biomarker measurements (amyloid deposits, neurodegeneration markers) were validated and reliably measured"
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[3]`: "Whether the open-label extension is scientifically justified or represents wishful thinking (the summary does not elabor"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.88"
    _Stated confidence level_
  - Note: 4 uncertainties (4 substantive)
  - Note: Confidence 0.88

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[1]`: "Could flag the open-label extension proposal as problematic if it implied confidence in future cognitive benefits—but th"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 include rejection reasoning

**Self Monitoring Quality:** 4.8/8
  - (+) `self_check[3]`: "Could the biomarker-cognition gap itself be problematic? Yes, but that's a scientific question about the drug/disease, n"
    _Most substantive self-verification step_
  - Note: 4 self-check items
  - Note: Self-check quality: 0 deep, 4 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 10.0/10
  - Note: Signal density: 0.71, 442 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "zed trial, biomarker success, honest reporting of cognitive failure, appropr"
    _Insight 'honest reporting' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "solid"
  - _Impacts: support_strength_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "solid"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['effect'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "solid"
  - _Impacts: support_strength, structural_reasoning_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: evidence_matches_claim
  - `(task expectation)`: "Expected: evidence_matches_claim"
  - _Impacts: insight_depth_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/10 content words)
  - `key_claims[0]`: "The study reports a genuine dissociation: strong biomarker effects without cognitive benefit"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/7 content words)
  - `key_claims[1]`: "The investigators do NOT overclaim—they explicitly state cognitive benefits are unproven"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/8 content words)
  - `key_claims[2]`: "This is an honest null finding on the primary clinical outcome, not hidden or minimized"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/8 content words)
  - `key_claims[3]`: "The proposal for further study is appropriately cautious given the cognitive failure"
- **[WARN]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Phenomenon is named but causal mechanism is not explained
  - `final_answer`: "solid"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 9309ms

**Final Answer:** solid

**Confidence:** 0.88

**Assumptions:**
- The trial was properly randomized and controlled (Phase 2/3 design implies this)
- Biomarker measurements (amyloid deposits, neurodegeneration markers) were validated and reliably measured
- Cognitive decline was measured using standard, validated instruments
- The trial had adequate statistical power and follow-up duration to detect cognitive effects if present
- The text accurately represents what the investigators concluded

**Reasoning Steps:**
1. Identified the core claim: drug reduced amyloid biomarkers but failed to slow cognitive decline
2. Checked for overclaim: The text does NOT claim cognitive benefit despite biomarker success. Investigators explicitly state cognitive benefits 'remain unproven'
3. Checked for mechanism vs. evidence: The text does not claim a mechanism explaining why biomarkers improved without cognitive benefit. It simply reports both findings
4. Checked for correlation vs. causation: The biomarker improvements are from a randomized trial (appropriate for causal inference about drug effects on biomarkers). The null finding on cognition is also from the same trial
5. Checked for decorative uncertainty: The acknowledgment that 'cognitive benefits remain unproven' is substantive, not decorative—it directly contradicts what one might expect from biomarker success
6. Checked for confounders: In a randomized trial, confounding is controlled by design. The null cognitive finding is not explained away
7. Evaluated the investigators' response: Proposing an open-label extension is reasonable given biomarker success, but they appropriately acknowledge the cognitive benefit gap rather than claiming it exists

**Key Claims:**
- The study reports a genuine dissociation: strong biomarker effects without cognitive benefit
- The investigators do NOT overclaim—they explicitly state cognitive benefits are unproven
- This is an honest null finding on the primary clinical outcome, not hidden or minimized
- The proposal for further study is appropriately cautious given the cognitive failure

**Alternative Hypotheses:**
- Could classify as 'overclaim' if the text had claimed cognitive benefits or suggested biomarker improvements necessarily predict clinical benefit—but it does not
- Could flag the open-label extension proposal as problematic if it implied confidence in future cognitive benefits—but the text frames it as exploratory given unproven cognitive effects

**Uncertainties:**
- Whether the trial had sufficient power and duration to detect a cognitive effect (not stated in the summary)
- Whether biomarker improvements in inherited Alzheimer's disease necessarily predict cognitive benefit in sporadic disease
- The specific cognitive measures used and their sensitivity
- Whether the open-label extension is scientifically justified or represents wishful thinking (the summary does not elaborate)

**Self-Verification:**
- Did I assume problems that aren't stated? No—the text is transparent about the cognitive null finding
- Did I miss an overclaim? No—the language 'remain unproven' is explicit and appropriate
- Is this a solid study report? Yes—randomized trial, biomarker success, honest reporting of cognitive failure, appropriate caveats
- Could the biomarker-cognition gap itself be problematic? Yes, but that's a scientific question about the drug/disease, not an epistemic flaw in how the results are reported

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 4.8/8 `######....`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 10.0/10 `##########`


## Final Verdict

**Solo run: Claude Haiku** scored **73.8/100**.

**Best per dimension:**
- Correctness: Claude Haiku (30.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (4.8/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (1.5/10)
- Communication Efficiency: Claude Haiku (10.0/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 9.3s | 73.8/100 | 7.9 |

Failure modes observed: missed_key_insight, named_not_explained, unsupported_conclusion, unsupported_intermediate_step.
